The trial will enrol 30 participants diagnosed with IgAN.

IgA nephropathy is a progressive disease where immune proteins damage the kidneys' filtering units. Treatment options include medications and lifestyle changes to help slow progression and manage ...

Interim Phase 2 JADE101 data are expected in 2027SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade ...

Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II ...

IgA nephropathy, also known as Berger’s disease, is a progressive, autoimmune, chronic kidney disease that predominantly affects adults between the ages of 20 and 40. It is characterized by the ...

IgA nephropathy (IgAN) is a kidney disorder caused by a buildup of immune complexes and the antibody called immunoglobulin A (IgA) inside the kidneys. This buildup causes inflammation in the kidneys.

Dr Suneel Udani vividly recalls, as a first-year fellow, caring for a patient with IgA nephropathy whose condition deteriorated despite their best efforts, due to the limited treatment options ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing immune complexes (IgA-ICs) in the glomerular mesangium, leading to mesangial ...

Panelists discuss how immunoglobulin A (IgA) nephropathy develops through a complex 4-hit cascade involving aberrant IgA1 glycosylation, anti-glycan antibody formation, immune complex deposition, and ...

The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...

Between 20 and 50 percent of individuals with IgA nephropathy will experience kidney failure within two decades of diagnosis, though the timeline varies significantly from person to person. Regular ...